| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.10B | +8.6% |
| Gross profit | ¥0.02B | — |
| Operating income | ¥-0.00B | — |
| Net income | ¥-0.00B | — |
| Gross margin | 15.6% | Net margin -0.1% |
| Revenue Q/Q | +5.9% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.09B | 84.4% |
| R&D | ¥0.00B | 2.3% |
| SG&A | ¥0.01B | 13.5% |
| Tax & other | ¥-0.00B | -0.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
迈赫股份 ・ 大族数控 ・ 诚达药业 ・ 朗威股份 ・ 国泰环保 ・ 联特科技 ・ 三元生物 ・ 华兰疫苗 ・ 中亦科技 ・ 联合化学 ・ 金杨精密 ・ 亨迪药业
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies